Sources: SHPH Website. SHPH Presentation.
-----
And as I mentioned above, (Nasdaq: SHPH) has several potential catalysts to consider this moment. Take a look:
No. 1 SHPH Potential Catalyst - Could This Low Float Create A Scenario For Strong Volatility Potential?
According to the Yahoo Finance website, SHPH has a low float.
In fact, the website reports this profile to have approximately 3.62Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the first half of 2025, could it provide a near term spark?
-----
No. 2 SHPH Potential Catalyst - Key Milestone Achieved As Phase 2 Clinical Trial Marches Forward.
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), ..., announced today that it has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma.
The Phase 2 trial design is to initially randomize 40 patients into two different dose levels, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients. Once the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating survival as compared to historical controls. The Phase 2 clinical trial is being conducted on patients presenting with the most aggressive form of brain tumors– IDH wild-type, methylation negative glioblastoma. This cohort of patients currently only have radiation as the standard of care, with less than half of the patients surviving beyond 12 months after diagnosis.
...
"Enrollment into the trial is ahead of our expectations," commented Shuttle Pharma's CEO and Chairman, Anatoly Dritschilo, M.D. "I am grateful to the teams at each of these nationally recognized cancer centers for their participation in the trial as we look to develop radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma."
...
-----
No. 3 SHPH Potential Catalyst - Shuttle Announces Sponsored Research Agreement With UCSF To Advance PSMA Development Program.
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), ..., today announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics, Inc.'s (a wholly-owned subsidiary of Shuttle Pharma) ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers.
"From a clinical perspective, PSMA is a valuable target for diagnosis and therapy of prostate cancer," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "In a discovery project to develop a novel, boron-containing PSMA ligand to enhance proton radiation therapy of prostate cancer, we discovered PSMA-B, a molecule containing boron and demonstrating nanomolar binding activity to PSMA. Preclinical evaluations have been initiated to explore the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, as well as a PET diagnostic reagent and as a targeted prostate cancer therapeutic. The agreement with UCSF will support further preclinical testing in a mouse model of prostate cancer for its potential to bind to prostate cancer deposits in mice."
Specifically, UCSF researchers, led by principal investigator, Robert Flavell, M.D., PhD., will aim to develop radiosynthetic methods for producing [18F]FPA-ACUPA probe; investigate cellular binding properties of [18F]FPA-ACUPA in PCa cell lines; and investigate the diagnostic potential of the probe across various PCa phenotypes. Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application with the US Patent and Trademark Office.
A significant opp... exists for PSMA ligands for prostate cancer diagnosis and treatment, particularly in the development of highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and targeted therapy delivery using radio labelled PSMA ligands. The Global PSMA PET Imaging Market reached $1.5Bn in 2022 and is expected to reach $2.0Bn by 2030. Pluvicto®, a targeted radiopharmaceutical treatment for PSMA-positive metastatic prostate cancer, has a predicted market size of $2Bn.
"We are excited to be working with Dr. Flavell and his team at UCSF to advance development of our PSMA-B ligand, a theranostic that has the potential to play a significant role in the future diagnosis and treatment of prostate cancer," Dr. Dritschilo concluded.
Read the full article here.
-----
No. 4 SHPH Potential Catalyst - Shuttle Announces Appointment Of Experienced Businessman, Christopher Cooper, As Co-CEO.
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), ..., today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities.
"I am excited to welcome Christopher Cooper as Co-CEO of Shuttle Pharma," commented Dr. Anatoly Dritschilo, Chairman of the Board and CEO of Shuttle Pharma. "Christopher brings a wealth of business acumen which when balanced with the inherent scientific expertise of the entire Shuttle Pharma team should allow for a highly effective executive structure that should inspire confidence going forward. I believe this appointment will enhance decision-making, supports fundraising, and prepares us for the accelerated achievement of key milestones in the future."
Christopher Cooper added, "I am enthusiastic to join the incredibly talented team at Shuttle Pharma as we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world. The Co-CEO structure will allow for parallel execution of R&D, regulatory and general business operations. I look forward to leveraging my business experience to allow Dr. Dritschilo to focus more of his efforts going forward on the successful execution of the Company's ongoing key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma and continued advancement of the Diagnostics subsidiary."
Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100Mn in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.
Read the full article here.
-----
No. 5 SHPH Potential Catalyst - Shuttle Creates Added Flexibility To Advance Phase 2 Clinical Trial.
Shuttle Pharma Pays Off Senior Secured Convertible Note
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"),..., today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note ("Note") issued on January 11, 2023.
...
"The elimination of the convertible note along with obtaining the bridge funding provides us with added flexibility to advance our ongoing Phase 2 clinical trial for the treatment of patients with glioblastoma," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "Over the past few months, Shuttle Pharma has made progress on a number of key activities. Along with our paydown of the convertible note and raising interim bridge funding, we have entered into agreements with six trial sites, five of which are now fully prepared to begin treating patients in the Phase 2 clinical trial. I look forward to maintaining our focus towards achieving our goal of increasing cancer cure rates, prolonging patient survival, and improving the quality of life for patients suffering from glioblastoma."
...
-----
(Nasdaq: SHPH) Recap - These Potential Catalysts Could Provide A Breakout Spark
No. 1 - Could This Low Float Create A Scenario For Strong Volatility Potential?
No. 2 - Key Milestone Achieved As Phase 2 Clinical Trial Marches Forward.
No. 3 - Shuttle Announces Sponsored Research Agreement With UCSF To Advance PSMA Development Program.
No. 4 - Shuttle Announces Appointment Of Experienced Businessman, Christopher Cooper, As Co-CEO.
No. 5 - Shuttle Creates Added Flexibility To Advance Phase 2 Clinical Trial.
-----
Coverage is officially initiated on Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH).
When updates are available, I'll have them out quickly. Talk soon.
Sincerely,
Kai Parker
StockWireNews
ليست هناك تعليقات:
إرسال تعليق